Related Experiment Videos
Experience with screening newborns for Duchenne muscular dystrophy in Wales
D M Bradley1, E P Parsons, A J Clarke
1Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff.
Insights
Newborn screening for Duchenne muscular dystrophy is acceptable to most families. This Duchenne muscular dystrophy (DMD) screening program in Wales identified nine affected families, with most reporting positive experiences.
Area of Science:
- Medical Genetics
- Newborn Screening
- Muscular Dystrophy Research
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder affecting newborn boys.
- Early diagnosis of DMD can potentially improve patient outcomes.
- Assessing the acceptability of newborn screening programs is crucial for implementation.
Purpose of the Study:
- To evaluate the acceptability of screening newborn boys for Duchenne muscular dystrophy.
- To assess family responses to early diagnosis of DMD.
- To compare experiences of families with early versus traditional diagnosis.
Main Methods:
- Informed consent-based screening offered to newborn boys in Wales.
- Utilized existing newborn screening sample programs (phenylketonuria, congenital hypothyroidism).
- Confirmed positive screens with creatine kinase, molecular genetic analysis, muscle biopsy, and dystrophin analysis.
Main Results:
- Screened 34,219 newborn boys, identifying nine affected families.
- Eight of the nine identified families reported a very positive experience with the screening program.
- Three families opted out of completing the diagnostic process.
Conclusions:
- The Duchenne muscular dystrophy newborn screening program demonstrates acceptability and should continue.
- The program provides a model for evaluating community-based genetic disease initiatives.
- Further evaluation is needed to fully understand the implications of early DMD diagnosis.
Objectives:
To assess the acceptability of screening newborn boys for Duchenne muscular dystrophy.
Design:
Screening is offered on the basis of informed consent in response to an information sheet entitled "A new test for baby boys--Do you want it?" The programme includes a prospective long term evaluation of family responses to early diagnosis and a comparison of their experiences and perceptions with those families who have undergone the later traditional clinical diagnosis.
Setting:
All maternity units throughout Wales. Samples obtained through screening programme for phenylketonuria and congenital hypothyroidism.
Subjects:
Those families whose son had a positive screening test.
Main Outcome Measures:
Creatine kinase activity. Venous blood test to confirm positive result. Molecular genetic mutation analysis. Muscle biopsy and dystrophin analysis. Qualitative measure of satisfaction among affected families.
Results:
34,219 Boys have been screened and nine affected families have been identified. Eight families were very positive about the programme. Three chose not to complete the diagnostic process.
Conclusion:
The programme should continue to permit a full evaluation of the issues involved and should serve as a model for other initiatives within the community for genetic disease.